Succinimidyl-4-formylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Succinimidyl-4-formylbenzamide
• 英文别名: 2-(2,5-dioxopyrrolidin-1-yl)-4-formylbenzamide
• 化学式: C₁₂H₁₀N₂O₄
• 分子量: 246.22
• InChiKey: NSWSKGOLDYBOIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  97.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• METHOD FOR THE DETECTION AND/OR QUANTIFICATION OF LUPIN BETA-CONGLUTIN ALLERGEN PROTEINS
  申请人：Consejo Superior de Investigaciones Científicas (CSIC)

  公开号：EP3514166A1

  公开（公告）日：2019-07-24

  The present invention provides an improved antibody, method and kit for the specific detection and/or quantification of the main allergen proteins of lupin seeds, namely beta-conglutins, preferably in foodstuffs. The method of the invention is preferably based on an ELISA assay and the antibody used has been designed against an epitope that is shared by at least seven isoforms of the beta-conglutin proteins of the Lupinus angustifolius species and at least one isoform of the Lupinis albus species. Thus, the method of the invention is highly specific and sensitive, so that it may detect and quantify even lupin traces present in food samples which might elicit allergic reactions in sensitized consumers.

  本发明提供了一种改进的抗体、方法和试剂盒，用于特异性检测和/或定量羽扇豆种子的主要过敏原蛋白，即β-凝集素，最好是食品中的β-凝集素。本发明的方法最好以 ELISA 检测法为基础，所使用的抗体是针对至少七种 Lupinus angustifolius 种的β-凝集素蛋白同工型和至少一种 Lupinis albus 种的β-凝集素蛋白同工型所共有的表位设计的。因此，本发明的方法具有高度的特异性和灵敏性，甚至可以检测和量化食品样品中可能引起过敏消费者过敏反应的羽扇豆痕量。
• THERAPEUTIC TARGET AND MONOCLONAL ANTIBODIES AGAINST IT FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER´S DISEASE
  申请人：Consejo Superior De Investigaciones Científicas

  公开号：EP3696192A1

  公开（公告）日：2020-08-19

  The invention provides a therapeutic target for the screening of drugs for the treatment of Alzheimer's disease (AD), as well as neutralizing monoclonal antibodies against said target and their use for the treatment of AD. The invention also refers to a kit comprising the antibodies and to an in vitro method for the diagnosis of AD in which preferably the antibodies or the kit comprising them are used.

  本发明提供了一种用于筛选治疗阿尔茨海默病（AD）药物的治疗靶点，以及针对上述靶点的中和单克隆抗体及其在AD治疗中的应用。本发明还涉及一种包含该抗体的试剂盒，以及一种体外诊断阿尔茨海默病的方法，在该方法中最好使用该抗体或包含该抗体的试剂盒。
• Oligonucleotide-mediated quantitative multiplexed immunoassays
  申请人：The University of Chicago

  公开号：US10550421B2

  公开（公告）日：2020-02-04

  Methods and compositions for quantitative immunoassays are provided, in which ligand-conjugated probes are used to label samples and ligand-surfaced microspheres are used as quantitative reference standards. Certain embodiments provide a method of quantitative flow cytometry where ligands are oligonucleotides, and a sample comprising one or more cells is contacted with a hybridized antibody::fluorophore labeled targeting construct to label the cells, and the labeled cells are analyzed. In some embodiments, a population of quantitative labeled oligospheres labeled with the same fluorescent label as the cells is analyzed using the flow cytometer and used to create a quantitative standard curve of cytometer intensity versus molecules fluorescent label per oligosphere event. A standard curve trendline is established and used to determine the molecules of fluorescent label per cellular event for the antigen-positive cell populations. Based on molecules of fluorescent label per cell, the amount of Antibody Binding per Cell (ABC) is quantified.

  提供了用于定量免疫测定的方法和组合物，其中配体结合探针用于标记样品，配体表面微球用作定量参考标准。某些实施方案提供了一种定量流式细胞术方法，其中配体是寡核苷酸，包含一个或多个细胞的样品与杂交抗体：：荧光团标记的靶向构建体接触以标记细胞，并对标记的细胞进行分析。在某些实施方案中，使用流式细胞仪分析与细胞具有相同荧光标记的定量标记寡核细胞群，并用于创建细胞仪强度与每个寡核细胞事件的分子荧光标记的定量标准曲线。建立标准曲线趋势线，用于确定抗原阳性细胞群每个细胞事件的荧光标签分子数。根据每个细胞的荧光标记分子数，量化每个细胞的抗体结合量 (ABC)。
• Nanozymes, methods of making nanozymes, and methods of using nanozymes
  申请人：University of Florida Research Foundation, Inc.

  公开号：US10538757B2

  公开（公告）日：2020-01-21

  Embodiments of the present disclosure provide for nanozymes that can include a therapeutic agent, methods of making nanozymes, methods of using nanozymes, and the like. In some embodiments, the nanozymes can include a shell that can surround a hollow core that can be configured to receive a compound and the shell can include a recognition moiety and an enzyme.

  本公开的实施方案提供了可包括治疗剂的纳米酶、制造纳米酶的方法、使用纳米酶的方法等。在一些实施例中，纳米酶可以包括一个外壳，该外壳可以包围一个中空的内核，该内核可以配置成接收化合物，外壳可以包括识别分子和酶。
• Multi component detection
  申请人：CELL SIGNALING TECHNOLOGY, INC.

  公开号：US10577640B2

  公开（公告）日：2020-03-03

  The disclosure provides methods for detecting the concurrent presence of at least two targets within a biological sample. The method includes contacting said biological sample with a first binding agent, said first binding agent operably linked to a first sortase molecule, wherein said first binding agent specifically binds to a first target; contacting said biological sample with a second binding agent, said second binding agent operably linked to a first sortase recognition sequence peptide, wherein said second binding agent specifically binds to a second target; adding a sortase substrate under conditions where a first sortase-mediated ligation of the sortase substrate to the first sortase recognition sequence will produce a ligation product, and detecting the ligation product wherein detection of said ligation product indicates the concurrent presence of the first target and the second target in the biological sample. Also disclosed are kits comprising reagents for performing the methods as claimed.

  本公开提供了检测生物样本中同时存在至少两个靶标的方法。该方法包括将所述生物样品与第一结合剂接触，所述第一结合剂与第一分选酶分子可操作地连接，其中所述第一结合剂特异性地与第一靶标结合；将所述生物样品与第二结合剂接触，所述第二结合剂与第一分选酶识别序列肽可操作地连接，其中所述第二结合剂特异性地与第二靶标结合；在分选酶介导的第一分选酶底物与第一分选酶识别序列连接将产生连接产物的条件下加入分选酶底物，并检测连接产物，其中所述连接产物的检测表明生物样品中同时存在第一靶标和第二靶标。还公开了包含试剂的试剂盒，用于执行所述方法。